Prelude Therapeutics Incorporated

PRLDNASDAQHealthcare● Active

$3.84

+$0.03(+0.79%)

Market Cap$218621864

P/E Ratio—

52W High$5.54

52W Low$0.75

Avg Volume384K

Open$3.86

Beta1.01

Cash on Hand Financials Revenue

Prelude Therapeutics Incorporated (PRLD) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

PRLD · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$103.2M▼ -22.8% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$35.3M

cashAndCashEquivalents

Short-Term Investments

$68.0M

shortTermInvestments

YoY Change vs Prior Year

-22.8%

vs prior fiscal year

Latest Quarter

$81.6M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$103.2MCash on Hand

Total Debt$17.8MTotal Debt

Net Cash / Net Debt+$85.4MNet Cash Position

Cash vs Debt Ratio

Cash 85%Prelude Therapeutics Incorporated cash as % of market cap: 47.21%% · MCap $0BDebt 15%

Prelude Therapeutics Incorporated has a net cash position of $85.4M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$103.2M − $17.8M = +$85.4M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

PRLD annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

PRLD cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$103.2M-22.8%

Dec 31, 2024FY$133.6M-42.6%

Dec 31, 2023FY$232.9M+15.5%

Dec 31, 2022FY$201.7M-30.7%

Dec 31, 2021FY$291.2M+33.4%

PRLD cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

PRLD vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Prelude Therapeutics IncorporatedYOU

PRLD

$103.2M$219M47.2%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Prelude Therapeutics Incorporated (PRLD) cash on hand as of December 31, 2025 is $103.2M, comprising $35.3M in cash and cash equivalents (CCE) plus $68.0M in short-term investments — reported as Prelude Therapeutics Incorporated cash and short-term investments on the balance sheet (10-K filing). Also referred to as Prelude Therapeutics Incorporated cash reserves or cash position.

Prelude Therapeutics Incorporated annual cash on hand history shows decreased -22.8% in 2025: decreased -22.8% in 2025. Prelude Therapeutics Incorporated cash reserves in 2025 reflect the company's capital allocation strategy.

Prelude Therapeutics Incorporated carries total debt of $17.8M against cash of $103.2M, resulting in a net cash position of +$85.4M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

PRLD cash on hand · 5 questions

As of December 31, 2025, Prelude Therapeutics Incorporated (PRLD) has $103,214,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $35,256,000 in cash and cash equivalents (CCE) plus $67,958,000 in short-term investments. Latest quarter (March 31, 2026): $81,554,000. Data sourced from the annual 10-K filing via FMP.

PRLD cash on handPRLD cash reservesPRLD cash 2025how much cash does PRLD have

▸ Source: FMP /balance-sheet-statement · US GAAP · Prelude Therapeutics Incorporated · Prelude Therapeutics Incorporated SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025